Carcinoid syndrome laboratory tests: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
{{Carcinoid syndrome}} | {{Carcinoid syndrome}} | ||
{{CMG}} | {{CMG}} | ||
Line 10: | Line 12: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Needs content]] | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] |
Revision as of 18:34, 10 September 2012
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Carcinoid syndrome laboratory tests On the Web |
American Roentgen Ray Society Images of Carcinoid syndrome laboratory tests |
Risk calculators and risk factors for Carcinoid syndrome laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
With a certain degree of clinical suspicion, diagnosis is made primarily by measuring plasma levels of the secreted glycoprotein Chromogranin A, supported by measuring the 24 hour urine levels of 5-HIAA (5-hydroxyindoleacetic acid), a breakdown product of serotonin. Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day.